相似文献
1
Efficacy of micafungin in combination with other drugs in a murine model of disseminated trichosporonosis.
Antimicrob Agents Chemother. 2005 Feb;49(2):497-502. doi: 10.1128/AAC.49.2.497-502.2005.
2
Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin.
Clin Infect Dis. 2006 Mar 15;42(6):753-7. doi: 10.1086/500323. Epub 2006 Feb 8.
3
Combined antifungal therapy in a murine infection by Candida glabrata.
J Antimicrob Chemother. 2006 Dec;58(6):1295-8. doi: 10.1093/jac/dkl395. Epub 2006 Sep 29.
4
Combined therapies in a murine model of blastoschizomycosis.
Antimicrob Agents Chemother. 2007 Jul;51(7):2608-10. doi: 10.1128/AAC.00173-07. Epub 2007 Apr 23.
5
Activities of flucytosine, fluconazole, amphotericin B, and micafungin in a murine model of disseminated infection by Candida glabrata.
Antimicrob Agents Chemother. 2005 Nov;49(11):4757-9. doi: 10.1128/AAC.49.11.4757-4759.2005.
6
The development of animal infection models and antifungal efficacy assays against clinical isolates of Trichosporon asahii, T. asteroides and T. inkin.
Virulence. 2015;6(5):476-86. doi: 10.1080/21505594.2015.1020273. Epub 2015 Mar 9.
7
In vitro pharmacodynamics and in vivo efficacy of fluconazole, amphotericin B and caspofungin in a murine infection by Candida lusitaniae.
Int J Antimicrob Agents. 2014 Feb;43(2):161-4. doi: 10.1016/j.ijantimicag.2013.10.024. Epub 2013 Nov 26.
8
Micafungin combined with fluconazole, an effective therapy for murine blastoschizomycosis.
J Antimicrob Chemother. 2008 Apr;61(4):877-9. doi: 10.1093/jac/dkn012. Epub 2008 Feb 13.
9
Efficacy of micafungin against deep-seated candidiasis in cyclophosphamide-induced immunosuppressed mice.
J Antimicrob Chemother. 2005 Apr;55(4):587-90. doi: 10.1093/jac/dki024. Epub 2005 Feb 22.
10
Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis.
Med Mycol. 2006 Feb;44(1):69-73. doi: 10.1080/13693780500148350.
引用本文的文献
1
Infective Endocarditis of Prosthetic Valve: A Case Report and Literature Review.
Antibiotics (Basel). 2023 Jul 13;12(7):1181. doi: 10.3390/antibiotics12071181.
2
prosthetic valve endocarditis managed with antifungal suppression therapy.
Med Mycol Case Rep. 2022 Feb 21;36:10-12. doi: 10.1016/j.mmcr.2022.02.004. eCollection 2022 Jun.
3
On and Under the Skin: Emerging Basidiomycetous Yeast Infections Caused by Trichosporon Species.
PLoS Pathog. 2015 Jul 30;11(7):e1004982. doi: 10.1371/journal.ppat.1004982. eCollection 2015 Jul.
4
The development of animal infection models and antifungal efficacy assays against clinical isolates of Trichosporon asahii, T. asteroides and T. inkin.
Virulence. 2015;6(5):476-86. doi: 10.1080/21505594.2015.1020273. Epub 2015 Mar 9.
5
Use of combination therapy to successfully treat breakthrough Trichosporon asahii infection in an acute leukemia patient receiving voriconazole.
Med Mycol Case Rep. 2014 Oct 19;6:55-7. doi: 10.1016/j.mmcr.2014.09.003. eCollection 2014 Oct.
6
A fatal case of Trichosporon asahii fungemia and pneumonia in a kidney transplant recipient during caspofungin treatment.
Ther Clin Risk Manag. 2014 Sep 30;10:759-62. doi: 10.2147/TCRM.S67299. eCollection 2014.
7
Current knowledge of Trichosporon spp. and Trichosporonosis.
Clin Microbiol Rev. 2011 Oct;24(4):682-700. doi: 10.1128/CMR.00003-11.
8
Experimental pathogenicity of a clinical isolate of Trichosporon dermatis in a murine model.
Mycopathologia. 2011 Nov;172(5):381-7. doi: 10.1007/s11046-011-9442-6. Epub 2011 Jul 13.
9
In vitro interaction of itraconazole with amphotericin B, caspofungin, and terbinafine against clinical isolates of Trichosporon asahii.
Mycopathologia. 2011 May;171(5):345-8. doi: 10.1007/s11046-010-9384-4. Epub 2010 Dec 14.
10
Comparison of echinocandin antifungals.
Ther Clin Risk Manag. 2007 Mar;3(1):71-97. doi: 10.2147/tcrm.2007.3.1.71.
本文引用的文献
1
In vitro antifungal susceptibilities of uncommon basidiomycetous yeasts.
Antimicrob Agents Chemother. 2004 Jul;48(7):2724-6. doi: 10.1128/AAC.48.7.2724-2726.2004.
2
Combination antifungal therapy.
Antimicrob Agents Chemother. 2004 Mar;48(3):693-715. doi: 10.1128/AAC.48.3.693-715.2004.
3
Echinocandin antifungal drugs.
Lancet. 2003 Oct 4;362(9390):1142-51. doi: 10.1016/S0140-6736(03)14472-8.
4
Newer antifungal therapy for emerging fungal pathogens.
Int J Infect Dis. 2003 Mar;7(1):5-20. doi: 10.1016/s1201-9712(03)90037-3.
5
Efficacy of micafungin alone or in combination against systemic murine aspergillosis.
Antimicrob Agents Chemother. 2003 Apr;47(4):1452-5. doi: 10.1128/AAC.47.4.1452-1455.2003.
6
Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia.
Eur J Clin Microbiol Infect Dis. 2002 Dec;21(12):892-6. doi: 10.1007/s10096-002-0841-y. Epub 2002 Nov 1.
7
In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.
Antimicrob Agents Chemother. 2002 Jan;46(1):245-7. doi: 10.1128/AAC.46.1.245-247.2002.
8
Multidrug-resistant Trichosporon asahii infection of nongranulocytopenic patients in three intensive care units.
J Clin Microbiol. 2001 Dec;39(12):4420-5. doi: 10.1128/JCM.39.12.4420-4425.2001.
9
Uncommon opportunistic fungi: new nosocomial threats.
Clin Microbiol Infect. 2001;7 Suppl 2:8-24. doi: 10.1111/j.1469-0691.2001.tb00005.x.
10
Trichosporon asahii, a non-Candida yeast that caused fatal septic shock in a patient without cancer or neutropenia.
Clin Infect Dis. 2001 Sep 1;33(5):E28-30. doi: 10.1086/322640. Epub 2001 Jul 26.
Zotero 插件